Tyrosine kinase (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tyrosine kinase" in English language version.

refsWebsite

Global rank English rank

28nih.gov

4^th place

20doi.org

2^nd place

5semanticscholar.org

11^th place

8^th place

4web.archive.org

1^st place

3harvard.edu

18^th place

17^th place

1zenodo.org

621^st place

380^th place

1niscair.res.in

low place

8,984^th place

1mskcc.org

low place

7,046^th place

1psu.edu

207^th place

136^th place

1handle.net

102^nd place

76^th place

doi.org

Hanks SK, Quinn AM, Hunter T (July 1988). "The protein kinase family: conserved features and deduced phylogeny of the catalytic domains". Science. 241 (4861): 42–52. Bibcode:1988Sci...241...42H. doi:10.1126/science.3291115. PMID 3291115.
Radha V, Nambirajan S, Swarup G (March 1996). "Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity". European Journal of Biochemistry. 236 (2): 352–359. doi:10.1111/j.1432-1033.1996.00352.x. PMID 8612602.
Ruetten H, Thiemermann C (September 1997). "Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase". British Journal of Pharmacology. 122 (1): 59–70. doi:10.1038/sj.bjp.0701345. PMC 1564904. PMID 9298529.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (June 1992). "pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 5192–5196. Bibcode:1992PNAS...89.5192S. doi:10.1073/pnas.89.11.5192. PMC 49256. PMID 1594631.
Dengjel J, Kratchmarova I, Blagoev B (October 2009). "Receptor tyrosine kinase signaling: a view from quantitative proteomics". Molecular BioSystems. 5 (10): 1112–1121. doi:10.1039/b909534a. PMID 19756300. Archived from the original on 2021-10-29. Retrieved 2019-09-06.
Wiley HS, Burke PM (January 2001). "Regulation of receptor tyrosine kinase signaling by endocytic trafficking". Traffic. 2 (1): 12–18. doi:10.1034/j.1600-0854.2001.020103.x. PMID 11208164. S2CID 7329602.
Rinker S, Ke Y, Liu Y, Chhabra R, Yan H (July 2008). "Self-assembled DNA nanostructures for distance-dependent multivalent ligand-protein binding". Nature Nanotechnology. 3 (7): 418–422. doi:10.1038/nnano.2008.164. PMC 2556356. PMID 18654566.
Silvennoinen O, Saharinen P, Paukku K, Takaluoma K, Kovanen P (July 1997). "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors". APMIS. 105 (7): 497–509. doi:10.1111/j.1699-0463.1997.tb05047.x. PMID 9269296. S2CID 21902484.
Modi V, Dunbrack RL (April 2019). "Defining a new nomenclature for the structures of active and inactive kinases". Proceedings of the National Academy of Sciences of the United States of America. 116 (14): 6818–6827. doi:10.1073/pnas.1814279116. PMC 6452665. PMID 30867294.
Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L (November 2007). "Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 7 (6): 594–611. doi:10.2174/187152007784111340. PMID 18045055.
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. (October 2003). "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial". JAMA. 290 (16): 2149–2158. doi:10.1001/jama.290.16.2149. PMID 14570950.
Sordella R, Bell DW, Haber DA, Settleman J (August 2004). "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways". Science. 305 (5687): 1163–1167. Bibcode:2004Sci...305.1163S. doi:10.1126/science.1101637. PMID 15284455. S2CID 34389318.
Okamoto I (January 2010). "Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy". The FEBS Journal. 277 (2): 309–315. doi:10.1111/j.1742-4658.2009.07449.x. PMID 19922468.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. (April 2001). "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia" (PDF). The New England Journal of Medicine. 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. S2CID 8399298. Archived from the original (PDF) on 2019-02-19.
García-Gutiérrez, Valentin; Breccia, Massimo; Jabbour, Elias; Mauro, Michael; Cortes, Jorge E. (11 July 2022). "A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase". Journal of Hematology & Oncology. 15 (1): 90. doi:10.1186/s13045-022-01309-0. PMC 9272596. PMID 35818053.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. (April 2001). "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor". The New England Journal of Medicine. 344 (14): 1052–1056. doi:10.1056/NEJM200104053441404. PMID 11287975.
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. (February 2008). "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT". Journal of Clinical Oncology. 26 (4): 620–625. CiteSeerX 10.1.1.690.6356. doi:10.1200/JCO.2007.13.4403. PMID 18235121.
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. (February 2008). "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia". Blood. 111 (4): 1834–1839. doi:10.1182/blood-2007-04-083196. hdl:11567/225870. PMID 18048643.
Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, et al. (May 2008). "Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors". Neoplasia. 10 (5): 489–500. doi:10.1593/neo.08200. PMC 2373870. PMID 18472966.
Rivera-Torres J, San José E (2019). "Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential". Frontiers in Pharmacology. 10: 1011. doi:10.3389/fphar.2019.01011. PMC 6759511. PMID 31619990.

handle.net

hdl.handle.net

le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. (February 2008). "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia". Blood. 111 (4): 1834–1839. doi:10.1182/blood-2007-04-083196. hdl:11567/225870. PMID 18048643.

harvard.edu

ui.adsabs.harvard.edu

Hanks SK, Quinn AM, Hunter T (July 1988). "The protein kinase family: conserved features and deduced phylogeny of the catalytic domains". Science. 241 (4861): 42–52. Bibcode:1988Sci...241...42H. doi:10.1126/science.3291115. PMID 3291115.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (June 1992). "pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 5192–5196. Bibcode:1992PNAS...89.5192S. doi:10.1073/pnas.89.11.5192. PMC 49256. PMID 1594631.
Sordella R, Bell DW, Haber DA, Settleman J (August 2004). "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways". Science. 305 (5687): 1163–1167. Bibcode:2004Sci...305.1163S. doi:10.1126/science.1101637. PMID 15284455. S2CID 34389318.

mskcc.org

Tontonoz, Matthew (December 27, 2017). "How a Chicken Helped Solve the Mystery of Cancer". Memorial Sloan Kettering Cancer Center. Archived from the original on 27 October 2022. Retrieved 27 October 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hanks SK, Quinn AM, Hunter T (July 1988). "The protein kinase family: conserved features and deduced phylogeny of the catalytic domains". Science. 241 (4861): 42–52. Bibcode:1988Sci...241...42H. doi:10.1126/science.3291115. PMID 3291115.
Radha V, Nambirajan S, Swarup G (March 1996). "Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity". European Journal of Biochemistry. 236 (2): 352–359. doi:10.1111/j.1432-1033.1996.00352.x. PMID 8612602.
Ruetten H, Thiemermann C (September 1997). "Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase". British Journal of Pharmacology. 122 (1): 59–70. doi:10.1038/sj.bjp.0701345. PMC 1564904. PMID 9298529.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (June 1992). "pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 5192–5196. Bibcode:1992PNAS...89.5192S. doi:10.1073/pnas.89.11.5192. PMC 49256. PMID 1594631.
Dengjel J, Kratchmarova I, Blagoev B (October 2009). "Receptor tyrosine kinase signaling: a view from quantitative proteomics". Molecular BioSystems. 5 (10): 1112–1121. doi:10.1039/b909534a. PMID 19756300. Archived from the original on 2021-10-29. Retrieved 2019-09-06.
Wiley HS, Burke PM (January 2001). "Regulation of receptor tyrosine kinase signaling by endocytic trafficking". Traffic. 2 (1): 12–18. doi:10.1034/j.1600-0854.2001.020103.x. PMID 11208164. S2CID 7329602.
Rinker S, Ke Y, Liu Y, Chhabra R, Yan H (July 2008). "Self-assembled DNA nanostructures for distance-dependent multivalent ligand-protein binding". Nature Nanotechnology. 3 (7): 418–422. doi:10.1038/nnano.2008.164. PMC 2556356. PMID 18654566.
Silvennoinen O, Saharinen P, Paukku K, Takaluoma K, Kovanen P (July 1997). "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors". APMIS. 105 (7): 497–509. doi:10.1111/j.1699-0463.1997.tb05047.x. PMID 9269296. S2CID 21902484.
Modi V, Dunbrack RL (April 2019). "Defining a new nomenclature for the structures of active and inactive kinases". Proceedings of the National Academy of Sciences of the United States of America. 116 (14): 6818–6827. doi:10.1073/pnas.1814279116. PMC 6452665. PMID 30867294.
Bhise SB, Nalawade AD, Wadhawa H (December 2004). "Role of protein tyrosine kinase inhibitors in cancer therapeutics". Indian Journal of Biochemistry & Biophysics. 41 (6): 273–280. PMID 22900354. Archived from the original on 2017-02-12. Retrieved 2017-02-11.
Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L (November 2007). "Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 7 (6): 594–611. doi:10.2174/187152007784111340. PMID 18045055.
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. (October 2003). "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial". JAMA. 290 (16): 2149–2158. doi:10.1001/jama.290.16.2149. PMID 14570950.
Sordella R, Bell DW, Haber DA, Settleman J (August 2004). "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways". Science. 305 (5687): 1163–1167. Bibcode:2004Sci...305.1163S. doi:10.1126/science.1101637. PMID 15284455. S2CID 34389318.
Okamoto I (January 2010). "Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy". The FEBS Journal. 277 (2): 309–315. doi:10.1111/j.1742-4658.2009.07449.x. PMID 19922468.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. (April 2001). "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia" (PDF). The New England Journal of Medicine. 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. S2CID 8399298. Archived from the original (PDF) on 2019-02-19.
García-Gutiérrez, Valentin; Breccia, Massimo; Jabbour, Elias; Mauro, Michael; Cortes, Jorge E. (11 July 2022). "A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase". Journal of Hematology & Oncology. 15 (1): 90. doi:10.1186/s13045-022-01309-0. PMC 9272596. PMID 35818053.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. (April 2001). "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor". The New England Journal of Medicine. 344 (14): 1052–1056. doi:10.1056/NEJM200104053441404. PMID 11287975.
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. (February 2008). "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT". Journal of Clinical Oncology. 26 (4): 620–625. CiteSeerX 10.1.1.690.6356. doi:10.1200/JCO.2007.13.4403. PMID 18235121.
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. (February 2008). "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia". Blood. 111 (4): 1834–1839. doi:10.1182/blood-2007-04-083196. hdl:11567/225870. PMID 18048643.
Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, et al. (May 2008). "Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors". Neoplasia. 10 (5): 489–500. doi:10.1593/neo.08200. PMC 2373870. PMID 18472966.
Rivera-Torres J, San José E (2019). "Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential". Frontiers in Pharmacology. 10: 1011. doi:10.3389/fphar.2019.01011. PMC 6759511. PMID 31619990.

ncbi.nlm.nih.gov

Ruetten H, Thiemermann C (September 1997). "Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase". British Journal of Pharmacology. 122 (1): 59–70. doi:10.1038/sj.bjp.0701345. PMC 1564904. PMID 9298529.
Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT (June 1992). "pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions". Proceedings of the National Academy of Sciences of the United States of America. 89 (11): 5192–5196. Bibcode:1992PNAS...89.5192S. doi:10.1073/pnas.89.11.5192. PMC 49256. PMID 1594631.
Rinker S, Ke Y, Liu Y, Chhabra R, Yan H (July 2008). "Self-assembled DNA nanostructures for distance-dependent multivalent ligand-protein binding". Nature Nanotechnology. 3 (7): 418–422. doi:10.1038/nnano.2008.164. PMC 2556356. PMID 18654566.
Modi V, Dunbrack RL (April 2019). "Defining a new nomenclature for the structures of active and inactive kinases". Proceedings of the National Academy of Sciences of the United States of America. 116 (14): 6818–6827. doi:10.1073/pnas.1814279116. PMC 6452665. PMID 30867294.
García-Gutiérrez, Valentin; Breccia, Massimo; Jabbour, Elias; Mauro, Michael; Cortes, Jorge E. (11 July 2022). "A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase". Journal of Hematology & Oncology. 15 (1): 90. doi:10.1186/s13045-022-01309-0. PMC 9272596. PMID 35818053.
Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, et al. (May 2008). "Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors". Neoplasia. 10 (5): 489–500. doi:10.1593/neo.08200. PMC 2373870. PMID 18472966.
Rivera-Torres J, San José E (2019). "Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential". Frontiers in Pharmacology. 10: 1011. doi:10.3389/fphar.2019.01011. PMC 6759511. PMID 31619990.

niscair.res.in

nopr.niscair.res.in

Bhise SB, Nalawade AD, Wadhawa H (December 2004). "Role of protein tyrosine kinase inhibitors in cancer therapeutics". Indian Journal of Biochemistry & Biophysics. 41 (6): 273–280. PMID 22900354. Archived from the original on 2017-02-12. Retrieved 2017-02-11.

psu.edu

citeseerx.ist.psu.edu

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. (February 2008). "Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT". Journal of Clinical Oncology. 26 (4): 620–625. CiteSeerX 10.1.1.690.6356. doi:10.1200/JCO.2007.13.4403. PMID 18235121.

semanticscholar.org

api.semanticscholar.org

Wiley HS, Burke PM (January 2001). "Regulation of receptor tyrosine kinase signaling by endocytic trafficking". Traffic. 2 (1): 12–18. doi:10.1034/j.1600-0854.2001.020103.x. PMID 11208164. S2CID 7329602.
Silvennoinen O, Saharinen P, Paukku K, Takaluoma K, Kovanen P (July 1997). "Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors". APMIS. 105 (7): 497–509. doi:10.1111/j.1699-0463.1997.tb05047.x. PMID 9269296. S2CID 21902484.
Sordella R, Bell DW, Haber DA, Settleman J (August 2004). "Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways". Science. 305 (5687): 1163–1167. Bibcode:2004Sci...305.1163S. doi:10.1126/science.1101637. PMID 15284455. S2CID 34389318.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. (April 2001). "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia" (PDF). The New England Journal of Medicine. 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. S2CID 8399298. Archived from the original (PDF) on 2019-02-19.

pdfs.semanticscholar.org

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. (April 2001). "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia" (PDF). The New England Journal of Medicine. 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. S2CID 8399298. Archived from the original (PDF) on 2019-02-19.

web.archive.org

Dengjel J, Kratchmarova I, Blagoev B (October 2009). "Receptor tyrosine kinase signaling: a view from quantitative proteomics". Molecular BioSystems. 5 (10): 1112–1121. doi:10.1039/b909534a. PMID 19756300. Archived from the original on 2021-10-29. Retrieved 2019-09-06.
Bhise SB, Nalawade AD, Wadhawa H (December 2004). "Role of protein tyrosine kinase inhibitors in cancer therapeutics". Indian Journal of Biochemistry & Biophysics. 41 (6): 273–280. PMID 22900354. Archived from the original on 2017-02-12. Retrieved 2017-02-11.
Tontonoz, Matthew (December 27, 2017). "How a Chicken Helped Solve the Mystery of Cancer". Memorial Sloan Kettering Cancer Center. Archived from the original on 27 October 2022. Retrieved 27 October 2022.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. (April 2001). "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia" (PDF). The New England Journal of Medicine. 344 (14): 1031–1037. doi:10.1056/NEJM200104053441401. PMID 11287972. S2CID 8399298. Archived from the original (PDF) on 2019-02-19.

zenodo.org

Dengjel J, Kratchmarova I, Blagoev B (October 2009). "Receptor tyrosine kinase signaling: a view from quantitative proteomics". Molecular BioSystems. 5 (10): 1112–1121. doi:10.1039/b909534a. PMID 19756300. Archived from the original on 2021-10-29. Retrieved 2019-09-06.